MY191802A - Trans-clomiphene metabolites and uses thereof - Google Patents

Trans-clomiphene metabolites and uses thereof

Info

Publication number
MY191802A
MY191802A MYPI2017001676A MYPI2017001676A MY191802A MY 191802 A MY191802 A MY 191802A MY PI2017001676 A MYPI2017001676 A MY PI2017001676A MY PI2017001676 A MYPI2017001676 A MY PI2017001676A MY 191802 A MY191802 A MY 191802A
Authority
MY
Malaysia
Prior art keywords
metabolites
trans
cancer
clomiphene
elevated
Prior art date
Application number
MYPI2017001676A
Other languages
English (en)
Inventor
Joseph S Podolski
Ronald D Wiehle
Original Assignee
Repros Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46724628&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY191802(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Repros Therapeutics Inc filed Critical Repros Therapeutics Inc
Publication of MY191802A publication Critical patent/MY191802A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MYPI2017001676A 2011-08-04 2012-08-03 Trans-clomiphene metabolites and uses thereof MY191802A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161515278P 2011-08-04 2011-08-04

Publications (1)

Publication Number Publication Date
MY191802A true MY191802A (en) 2022-07-15

Family

ID=46724628

Family Applications (2)

Application Number Title Priority Date Filing Date
MYPI2017001676A MY191802A (en) 2011-08-04 2012-08-03 Trans-clomiphene metabolites and uses thereof
MYPI2014000022A MY170718A (en) 2011-08-04 2012-08-03 Trans-clomiphene metabolites and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
MYPI2014000022A MY170718A (en) 2011-08-04 2012-08-03 Trans-clomiphene metabolites and uses thereof

Country Status (21)

Country Link
US (1) US9981906B2 (enExample)
EP (2) EP3351527A1 (enExample)
JP (2) JP6433785B2 (enExample)
KR (1) KR20140054110A (enExample)
CN (1) CN103702975B (enExample)
AU (2) AU2012289964B2 (enExample)
BR (1) BR112014000908A2 (enExample)
CA (1) CA2841572C (enExample)
CL (1) CL2014000268A1 (enExample)
CO (1) CO6862154A2 (enExample)
CR (1) CR20140124A (enExample)
EA (1) EA201490416A1 (enExample)
IL (1) IL230287B (enExample)
MX (1) MX355316B (enExample)
MY (2) MY191802A (enExample)
NI (1) NI201400008A (enExample)
PH (1) PH12014500144A1 (enExample)
SG (1) SG10201606425WA (enExample)
UA (1) UA113291C2 (enExample)
WO (1) WO2013020017A1 (enExample)
ZA (1) ZA201400406B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120284764A1 (en) * 2011-05-05 2012-11-08 Keith Ball Method and system for requesting services by a media device
UA113291C2 (xx) 2011-08-04 2017-01-10 Метаболіти транскломіфену і їх застосування
MX363640B (es) 2012-05-31 2019-03-28 Repros Therapeutics Inc Formulaciones y metodos para la administracion vaginal de antiprogestinas.
ES2688821T3 (es) 2012-11-02 2018-11-07 Repros Therapeutics Inc. Métodos y composiciones para tratar afecciones dependientes de la progesterona
HK1216502A1 (zh) * 2012-11-02 2016-11-18 Repros Therapeutics Inc. 用於癌症治療的反式-克羅米芬
EP3402471A4 (en) * 2016-01-12 2019-08-28 Repros Therapeutics Inc. TRANS-CLOMIPHENE-BASED POLY THERAPY AND PROGESTERONE RECEPTOR ANTAGONIST FOR THE TREATMENT OF HORMONE-DEPENDENT PATHOLOGICAL CONDITIONS
US20190054044A1 (en) * 2016-02-25 2019-02-21 Aspen Park Pharmaceuticals, Inc. Oral dosage form of both clomiphene isomers and method of using same to treat secondary hypogonadism and minimize drug side effects in men
WO2017182097A1 (en) 2016-04-22 2017-10-26 F.I.S. - Fabbrica Italiana Sintetici S.P.A. Process for the preparation of enclomiphene citrate having needle shaped crystal habit.

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2914563A (en) 1957-08-06 1959-11-24 Wm S Merrell Co Therapeutic composition
IT951631B (it) 1971-03-18 1973-07-10 Richardson Merrell Spa Composti utili per la separazione di isomeri ottici geometrici e strutturali e relativo procedimen to di sintesi
US4061733A (en) 1976-10-15 1977-12-06 Narayan Vishwanath Gunjikar Veterinary compositions for inducing estrus in animals and method
US4729999A (en) 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
EP0206021B1 (de) 1985-06-08 1988-08-10 ASTA Pharma AG Neue Derivate des 1,1,2,2-Tetramethyl-1,2-bis-(2-fluor-4-hydroxyphenyl)-ethans
US4820736A (en) * 1987-03-20 1989-04-11 Yale University Use of clomiphene to predict fertility in a human female
GB8926171D0 (en) 1989-11-20 1990-01-10 Applied Research Systems Treatment of infertility
JPH04312522A (ja) 1991-04-08 1992-11-04 Yoshiaki Kawashima 徐放性錠剤の製造方法
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5681585A (en) 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
DE69316633T2 (de) * 1992-09-15 1998-05-20 Merrell Dow Pharmaceuticals Inc., Cincinnati, Ohio Nichtmetabolisierbare clomiphene-analoge zur behandlung von tamoxifen-resistenten tumoren
US5776923A (en) 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
GB9405304D0 (en) 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
JPH10501814A (ja) 1994-06-17 1998-02-17 ユニバーシティ・オブ・ネブラスカ・ボード・オブ・リージェンツ 生物的作用物質用のイン・シツゲル形成デリバリービヒクルおよびその使用方法
DE4435368A1 (de) 1994-09-22 1996-03-28 Schering Ag Verwendung von Aromatasehemmern zur Herstellung eines Arzneimittels zur Behandlung eines relativen Androgenmangels beim Mann
EP0844870B1 (en) 1995-08-17 2001-11-21 Csir Controlled release products
US5773031A (en) 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
IL120262A (en) 1996-02-28 2001-01-28 Pfizer Droloxifene and derivatives thereof for use in increasing serum testosterone levels
ATE277739T1 (de) 1996-10-28 2004-10-15 Gen Mills Inc Einbettung und einkapselung von teilchen zur kontrollierten abgabe
CN1256700A (zh) 1997-04-03 2000-06-14 吉尔福德药物有限公司 生物降解对苯二甲酸酯聚酯-聚磷酸酯聚合物、组合物、制品及其制备和使用方法
US6653297B1 (en) 1997-07-03 2003-11-25 Medical College Of Hampton Roads Control of selective estrogen receptor modulators
US6342250B1 (en) 1997-09-25 2002-01-29 Gel-Del Technologies, Inc. Drug delivery devices comprising biodegradable protein for the controlled release of pharmacologically active agents and method of making the drug delivery devices
US20040186185A1 (en) 1998-05-07 2004-09-23 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
US6413533B1 (en) 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
BR9912559A (pt) 1998-07-30 2001-10-09 Stoller Ets Tratamento de plantas com ácido salicìlico e aminas orgânicas
WO2000007996A2 (en) 1998-08-07 2000-02-17 Chiron Corporation Pyrazoles as estrogen receptor modulators
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
CA2376797C (en) 1999-06-11 2011-03-22 Watson Pharmaceuticals, Inc. Administration of non oral androgenic steroids to women
CA2321321A1 (en) 1999-09-30 2001-03-30 Isotis B.V. Polymers loaded with bioactive agents
US6258802B1 (en) 1999-10-06 2001-07-10 Medical College Of Hampton Roads Corticoid therapy
AU3104301A (en) 2000-01-20 2001-07-31 Noven Pharmaceuticals, Inc. Compositions and methods to effect the release profile in the transdermal administration of active agents
CN1400904A (zh) 2000-01-28 2003-03-05 恩多研究公司 与雌激素联合的选择性雌激素受体调节剂
US7067557B2 (en) 2000-05-26 2006-06-27 Harry Fisch Methods of treating androgen deficiency in men using selective antiestrogens
CA2409647C (en) 2000-05-26 2012-07-03 Harry Fisch Methods of treating androgen deficiency in men using selective antiestrogens
MXPA03001245A (es) 2000-08-11 2003-05-27 Wyeth Corp Metodo para el tratamiento del carcionma positivo para receptores de estrogeno.
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20040192598A1 (en) 2000-10-11 2004-09-30 Laura Kragie Composition and method of alleviating adverse side effects and/or enhancing efficacy of agents that inhibit aromatase
AU2002245104B2 (en) 2000-12-11 2006-08-17 Testocreme, Llc Topical testosterone formulations and associated methods
JP4845165B2 (ja) 2001-07-09 2011-12-28 リプロス セラピューティクス インコーポレイテッド 男性におけるテストステロン欠損の処置のための方法および物質
US7173064B2 (en) 2001-07-09 2007-02-06 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene for treating wasting and lipodystrophy
US6645974B2 (en) 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof
WO2003026568A2 (en) 2001-09-21 2003-04-03 Merck & Co., Inc. Androstanes as androgen receptor modulators
US20060269611A1 (en) 2001-11-29 2006-11-30 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US7105679B2 (en) 2001-12-19 2006-09-12 Kanojia Ramesh M Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US20050042268A1 (en) 2003-07-16 2005-02-24 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
EP1776098A1 (en) 2004-07-14 2007-04-25 Repros Therapeutics Inc. Trans-clomiphene for the treatment of benign prostate hypertrophy, prostate cancer, hypogonadism, elevated triglycerides and high cholesterol
US20060293294A1 (en) 2004-09-03 2006-12-28 Hormos Medical Corporation Method for treatment or prevention of androgen deficiency
CN101115709B (zh) * 2004-12-13 2011-04-13 小野药品工业株式会社 氨基羧酸衍生物及其医药用途
PL219509B1 (pl) * 2005-02-04 2015-05-29 Repros Therapeutics Inc Zastosowanie kompozycji zawierającej trans-klomifen
JP2008537538A (ja) 2005-02-11 2008-09-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｖｅｇｆ拮抗剤及び降圧剤の治療的組み合わせ
RU2413508C2 (ru) 2005-03-22 2011-03-10 Репрос Терапьютикс Инк. Режимы дозирования транс-кломифена
EP1896134A2 (en) 2005-06-13 2008-03-12 Rigel Pharmaceuticals, Inc. Methods and compositions for treating degenerative bone disorders
AU2006278599A1 (en) * 2005-08-05 2007-02-15 Repros Therapeutics Inc. Methods and compositions for treating female infertility using clomiphene
US7613937B2 (en) 2005-10-31 2009-11-03 Hewlett-Packard Development Company, L.P. Method and apparatus for utilizing a microcontroller to provide an automatic order and timing power and reset sequencer
EP1991241A4 (en) 2006-02-23 2009-07-08 Iomedix Sleep Internat Srl COMPOSITIONS AND METHODS FOR INTRODUCING AND MAINTAINING HIGH-QUALITY SLEEPING
EP1829534A1 (en) 2006-03-02 2007-09-05 Laboratorios Del Dr. Esteve, S.A. Use of compounds binding to the sigma receptor for the treatment of metabolic syndrome
US20080112888A1 (en) 2006-06-30 2008-05-15 Schering Corporation Igfbp2 biomarker
ES2358546T3 (es) 2007-06-26 2011-05-11 Media Patents, S. L. Router para administrar grupos multicast.
WO2009020521A2 (en) 2007-08-03 2009-02-12 The Brigham And Women's Hospital, Inc. Identification and treatment of estrogen responsive prostate tumors
KR101493472B1 (ko) 2007-10-16 2015-02-16 레프로스 쎄라피우틱스 아이엔씨. 대사증후군 치료를 위한 트랜스―클로미펜
US20100111901A1 (en) 2008-11-03 2010-05-06 Auspex Pharmaceuticals, Inc. Triazole inhibitors of aromatase
TWI458478B (zh) 2008-11-07 2014-11-01 Repros Therapeutics Inc 用於代謝症候群與第２型糖尿病的反式氯米芬
US20100144687A1 (en) 2008-12-05 2010-06-10 Glaser Rebecca L Pharmaceutical compositions containing testosterone and an aromatase inhibitor
UA113291C2 (xx) 2011-08-04 2017-01-10 Метаболіти транскломіфену і їх застосування
WO2013020215A1 (en) 2011-08-09 2013-02-14 Adams Kenneth W Use of aromatase inhibitor or estrogen blocker for increasing spermatogenesis or testosterone levels in males
ES2681023T3 (es) 2012-02-29 2018-09-11 Repros Therapeutics Inc. Terapia de combinación para tratar el déficit de andrógenos
EP2887922A1 (en) 2012-08-21 2015-07-01 Repros Therapeutics Inc. Trans-clomiphene formulations and uses thereof
CN103351304B (zh) 2013-07-01 2015-12-09 暨明医药科技（苏州）有限公司 一种克罗米芬的合成方法

Also Published As

Publication number Publication date
CO6862154A2 (es) 2014-02-10
SG10201606425WA (en) 2016-09-29
CR20140124A (es) 2014-05-13
NI201400008A (es) 2015-12-10
AU2012289964A1 (en) 2014-01-30
US9981906B2 (en) 2018-05-29
UA113291C2 (xx) 2017-01-10
CA2841572A1 (en) 2013-02-07
MX355316B (es) 2018-04-16
KR20140054110A (ko) 2014-05-08
BR112014000908A2 (pt) 2017-02-21
PH12014500144A1 (en) 2014-02-24
EA201490416A1 (ru) 2014-11-28
US20140163114A1 (en) 2014-06-12
CA2841572C (en) 2020-10-13
ZA201400406B (en) 2014-11-26
MY170718A (en) 2019-08-27
CN103702975A (zh) 2014-04-02
JP6433785B2 (ja) 2018-12-05
IL230287B (en) 2019-07-31
CL2014000268A1 (es) 2014-11-14
AU2012289964B2 (en) 2017-03-23
HK1196349A1 (zh) 2014-12-12
NZ621892A (en) 2016-03-31
JP2019023210A (ja) 2019-02-14
MX2014000825A (es) 2014-02-27
IL230287A0 (en) 2014-03-06
AU2017204171A1 (en) 2017-07-13
CN103702975B (zh) 2016-03-16
EP2744777A1 (en) 2014-06-25
EP3351527A1 (en) 2018-07-25
WO2013020017A1 (en) 2013-02-07
JP2014529584A (ja) 2014-11-13

Similar Documents

Publication Publication Date Title
PH12014500144A1 (en) Trans-clomiphene metabolites and uses thereof
PH12015500331A1 (en) Trans-clomiphene formulations and uses thereof
CA2871471C (en) Dna-pk inhibitors
MY157124A (en) Substituted imidazopyridinyl-aminopyridine compounds
PH12012501337A1 (en) Substituted pyrrolo-aminopyrimidine compounds
PH12014502772A1 (en) Substituted tricyclic compounds as fgfr inhibitors
PH12013502565A1 (en) Substituted imidazopyridinyl-aminopyridine compounds
PH12012501957B1 (en) Organosilicones
MX2012010434A (es) Compuestos y composiciones novedosas para atacar a las celulas madre del cancer.
IN2012DN02081A (enExample)
AU2016219704A1 (en) Anti-Notch1 antibodies
AU2012208283A8 (en) Antioxidant, anti-inflammatory, anti-radiation, metal chelating compounds and uses thereof
IN2014DN06104A (enExample)
GEP201706626B (en) Synthesis of (s)-nifuratel
PH12012501556A1 (en) Substituted naphthalenyl-pyrimidine compounds
MX2015012523A (es) Metodos para elaborar composiciones antineoplasicas.
IN2013DE03665A (enExample)
PH12016502133A1 (en) Substituted tricycle compounds as fgfr inhibitors
UA52377U (en) hydrophobic composition
UA76841U (en) Feed additive "echinobioactive"